Alivus Life Sciences holds 14th AGM, approves dividend and auditors

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) successfully conducted its 14th annual general meeting (AGM) on Monday, September 8, 2025, via video conference. The meeting concluded with the approval of all five ordinary resolutions by requisite majority.

Key approvals included the adoption of the audited financial statements for the fiscal year ended March 31, 2025, and the declaration of a final dividend of INR 5 per equity share for the same period. Additionally, shareholders approved the re-appointment of Vinod Naik as a director and ratified the remuneration for M/s. Kirit Mehta & Associates as cost auditors for the fiscal year ending March 31, 2026.

M/s. Bhadresh Shah & Associates were also appointed as the secretarial auditor for the company. The scrutinizer's report, confirming the e-voting results, was received on the same day and will be made available on the company’s website.